Summary of the Financial Results
Segment-wise operational performance
The Pharmaceuticals business registered Net Revenue from Operations of ` 6,562.3 million representing a decrease of 4.9 percent over the previous year. Expansion of National List of Essential Medicines (NLEM) has led to increase in the scope of drugs subject to price control.
Additionally there was a 2.71 percent reduction in prices from April 2016 following a reduction in the annual Wholesale Price Index (WPI) as per the Drugs Price Control Order, 2013 (“DPCO”). Both these events continue to have an adverse impact on the operating profits of the Pharmaceutical business. To mitigate the DPCO impact, cost containment measures were undertaken by the Company during the year to protect its operating profit. Following brands hold key positions in major therapeutic areas such as:
Central Nervous System: Tegrital®
Pain & Inflammation: Voveran®
Transplantation/Immunology: Sandimmun® Neoral®
Click here to get full report
Segment-wise operational performance
The Pharmaceuticals business registered Net Revenue from Operations of ` 6,562.3 million representing a decrease of 4.9 percent over the previous year. Expansion of National List of Essential Medicines (NLEM) has led to increase in the scope of drugs subject to price control.
Additionally there was a 2.71 percent reduction in prices from April 2016 following a reduction in the annual Wholesale Price Index (WPI) as per the Drugs Price Control Order, 2013 (“DPCO”). Both these events continue to have an adverse impact on the operating profits of the Pharmaceutical business. To mitigate the DPCO impact, cost containment measures were undertaken by the Company during the year to protect its operating profit. Following brands hold key positions in major therapeutic areas such as:
Central Nervous System: Tegrital®
Pain & Inflammation: Voveran®
Transplantation/Immunology: Sandimmun® Neoral®
Click here to get full report